AU3438900A - Use of trehalose for stabilising a liquid vaccine - Google Patents

Use of trehalose for stabilising a liquid vaccine

Info

Publication number
AU3438900A
AU3438900A AU34389/00A AU3438900A AU3438900A AU 3438900 A AU3438900 A AU 3438900A AU 34389/00 A AU34389/00 A AU 34389/00A AU 3438900 A AU3438900 A AU 3438900A AU 3438900 A AU3438900 A AU 3438900A
Authority
AU
Australia
Prior art keywords
trehalose
stabilising
liquid vaccine
vaccine composition
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU34389/00A
Inventor
Jean-Rene Cartier
Sandrine Lentsch-Graf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur SA filed Critical Aventis Pasteur SA
Publication of AU3438900A publication Critical patent/AU3438900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention concerns a liquid vaccine composition comprising at least an antigen consisting of a polysaccharide bound to a carrier protein and trehalose. The invention also concerns a method for stabilising a liquid vaccine composition which consists in adding trehalose to the vaccine composition.
AU34389/00A 1999-03-23 2000-03-23 Use of trehalose for stabilising a liquid vaccine Abandoned AU3438900A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9903765A FR2791895B1 (en) 1999-03-23 1999-03-23 USE OF TREHALOSE TO STABILIZE A LIQUID VACCINE
FR9903765 1999-03-23
PCT/FR2000/000730 WO2000056365A1 (en) 1999-03-23 2000-03-23 Use of trehalose for stabilising a liquid vaccine

Publications (1)

Publication Number Publication Date
AU3438900A true AU3438900A (en) 2000-10-09

Family

ID=9543654

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34389/00A Abandoned AU3438900A (en) 1999-03-23 2000-03-23 Use of trehalose for stabilising a liquid vaccine

Country Status (11)

Country Link
EP (1) EP1163008B1 (en)
JP (1) JP2002540079A (en)
AT (1) ATE246937T1 (en)
AU (1) AU3438900A (en)
CA (1) CA2366869A1 (en)
DE (1) DE60004496T2 (en)
DK (1) DK1163008T3 (en)
ES (1) ES2200845T3 (en)
FR (1) FR2791895B1 (en)
PT (1) PT1163008E (en)
WO (1) WO2000056365A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737413T2 (en) 1996-01-04 2007-10-31 Novartis Vaccines and Diagnostics, Inc., Emeryville BACTERIOFERRITINE FROM HELICOBACTER PYLORI
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
PT2353608T (en) 2002-10-11 2020-03-11 Novartis Vaccines And Diagnostics S R L Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
US10272147B2 (en) 2003-01-30 2019-04-30 Glaxosmithkline Biologicals S.A. Injectable vaccines against multiple meningococcal serogroups
PT1961426E (en) 2003-10-02 2011-06-28 Novartis Vaccines & Diagnostic Combined meningitis vaccines
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
US9642907B2 (en) * 2006-05-12 2017-05-09 Bharat Biotech International Limited Stabilized liquid rotavirus vaccine composition
AU2007293672B2 (en) 2006-09-07 2013-06-27 Glaxosmithkline Biologicals S.A. Vaccine
AR066376A1 (en) 2007-05-02 2009-08-12 Glaxosmithkline Biolog Sa VACCINE
WO2009035707A1 (en) 2007-09-14 2009-03-19 Acambis Inc. Pharmaceutical compositions containing clostridium difficile toxoids a and b
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
BR112012009014B8 (en) 2009-09-30 2022-10-04 Novartis Ag PROCESS FOR PREPARING S. AUREUS CAPSULAR POLYSACCHARIDE CONJUGATE TYPE 5 OR TYPE 8 AND CRM197 TRANSPORT MOLECULE, CONJUGATE AND IMMUNOGENIC COMPOSITION
JP2013521327A (en) 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic composition
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
GB201016969D0 (en) 2010-10-08 2010-11-24 Genome Res Ltd Expression system
CN102793919A (en) 2011-05-20 2012-11-28 日东电工株式会社 Pharmaceutical composition and method for producing the same
TR201909110T4 (en) 2011-09-14 2019-07-22 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates.
EP2788477A2 (en) 2011-12-07 2014-10-15 Institut Pasteur Identification of a swine parecho-like virus and applications
SG11201407440WA (en) 2012-05-22 2014-12-30 Novartis Ag Meningococcus serogroup x conjugate
FR2992656B1 (en) * 2012-07-02 2016-10-07 Sanofi Pasteur METHOD FOR PRODUCING ANTIGENS HAEMOPHILUS INFLUENZAE TYPE B
WO2014009971A2 (en) * 2012-07-07 2014-01-16 Bharat Biotech International Limited Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
WO2014053612A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic composition
SI3421997T1 (en) * 2012-12-28 2020-10-30 Cellestis Limited A cell mediated immune response assay
WO2017175082A1 (en) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
CN118236477A (en) 2016-09-02 2024-06-25 赛诺菲巴斯德股份有限公司 Neisseria meningitidis vaccine
WO2018048869A1 (en) 2016-09-06 2018-03-15 Bioventures, Llc Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors
WO2018158457A1 (en) 2017-03-03 2018-09-07 Treos Bio Zrt Population-based immunogenic peptide identification platform
EP3369431A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Vaccine
EP3370065A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Immunogenic peptides
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
CN113329761A (en) 2018-09-04 2021-08-31 特雷斯生物有限公司 Peptide vaccine
CN112996538A (en) 2018-11-06 2021-06-18 葛兰素史密丝克莱恩生物有限公司 Immunogenic compositions
GB201908332D0 (en) 2019-06-11 2019-07-24 Univ Oxford Innovation Ltd Assays and inhibitors of oxygen-dependent N-terminal oxidation
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
KR20230017373A (en) 2020-04-03 2023-02-03 펩티씨 백신즈 리미티드 coronavirus vaccine
WO2022268916A2 (en) 2021-06-23 2022-12-29 Ose Immunotherapeutics Pan-coronavirus peptide vaccine
GB202109082D0 (en) 2021-06-24 2021-08-11 Univ Oxford Innovation Ltd Polypeptides and uses thereof
WO2023148333A1 (en) 2022-02-03 2023-08-10 CeCaVa GmbH & Co. KG Co-vaccination with cd4 and cd8 antigens
GB202208695D0 (en) 2022-06-14 2022-07-27 Univ Oxford Innovation Ltd Antibacterials

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2748132A1 (en) * 1977-10-27 1979-05-03 Behringwerke Ag STABILIZER FOR POLYSACCHARIDE
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
DK0626452T3 (en) * 1993-05-17 2000-02-14 Akzo Nobel Nv Vaccine against infection of Streptococcus suis
ES2194911T3 (en) * 1994-06-02 2003-12-01 Elan Drug Delivery Ltd METHOD FOR AVOIDING PROTEIN / PEPTIDES AGGREGATION WHEN YOUR REHYDRATION OR DEFROSTING IS LOCATED.
AU739916B2 (en) * 1996-09-26 2001-10-25 Merck Sharp & Dohme Corp. Rotavirus vaccine formulations
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines

Also Published As

Publication number Publication date
DE60004496T2 (en) 2004-04-08
PT1163008E (en) 2003-12-31
EP1163008A1 (en) 2001-12-19
FR2791895B1 (en) 2001-06-15
JP2002540079A (en) 2002-11-26
WO2000056365A1 (en) 2000-09-28
DK1163008T3 (en) 2003-11-17
EP1163008B1 (en) 2003-08-13
ATE246937T1 (en) 2003-08-15
FR2791895A1 (en) 2000-10-13
CA2366869A1 (en) 2000-09-28
ES2200845T3 (en) 2004-03-16
DE60004496D1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
AU3438900A (en) Use of trehalose for stabilising a liquid vaccine
ZA979550B (en) Method for the preparation of methylidene malonate nanoparticles, nanoparticles which optionally contain one or more biologically active molecules, and pharmaceutical compositions containing them.
IL160001A0 (en) Peptide based multimeric targeted contrast agents and methods for the preparation thereof
UA93855C2 (en) Neutralizing epitope-based growth enhancing vaccine
MY125202A (en) Vaccine
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
AU2903999A (en) Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
WO2001034801A3 (en) Recombinant gelatin in vaccines
AU2001233027A1 (en) Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
AU2001259631A1 (en) Methods and vectors for generating antibodies in avian species and uses therefor
HUP0203167A3 (en) Peptidic substances, their preparations and their use as complement protease inhibitors
WO2003104425A3 (en) Novel stable anti-cd22 antibodies
GEP20043349B (en) Methods of Controlling Cutworm Pests
AU4100199A (en) Compositions and methods for enhancing protein anabolism and detoxification
ZA200104189B (en) Method to produce inactivated w/o emulsion adjuvated vaccines.
MXPA02003232A (en) Compositions and methods for altering gene expression.
AU2002309486A8 (en) Methods and compositions for modulating the immune system of animals
ATE245028T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING TRIMEGESTONE
ZA979295B (en) Methods and compositions for delivery and expression of interferon-Ó nucleic acids.
AU2002368056A1 (en) Novel pla2 enzyme, it's antibody, enzyme inhibitor and use and the preparation methods thereof
AU7216498A (en) Inhibitors of the urokinase receptor
AU1615701A (en) Compositions and methods for regulating tumor-associated antigen expression
NZ514027A (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
AU4866201A (en) Compositions and methods for use in modulating immune system function
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase